Figure S1 from Everolimus Inhibits the Progression of Ductal Carcinoma In Situ to Invasive Breast Cancer Via Downregulation of MMP9 Expression
Year: 2023
Type: other
Abstract: mTOR inhibition decreases MMP9 expression. A, Everolimus treatment for 24 hours did not reduced MMP2 protein levels in SUM225 cells. B, C and D figures were the MMP-9 IHC quantification data measuring average optical density using ImageJ d 1.47 software. B, one-week Everolimus treatments at 2 mg/kg/day significantly decreased MMP9 protein levels in the mammary gland of MMTV/neu mice (n=3). C, one-week-Everolimus treatments at 2 mg/kg decreased MMP9 protein levels in the mammary gland of SUM225-MIND mouse mammary tissues detected by IHC (n=4). D, one-week-rapamycin treatments at 2 mg/day reduced MMP9 protein levels in mammary glands of DCIS patients detected by IHC. **p<0.01 and * p<0.05 represents the comparison between control vehicle and everolimus treatment groups or pre-treatment and post-treatment group, respectively, t-test.
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361938523